losartan-potassium and Abnormalities--Drug-Induced

Recombinant human erythropoietin (rHuEPO) is the standard of care for patients with chemotherapy-related anemia. Intravenous (IV) iron improves hemoglobin (Hb) response and decreases dosage requirements in patients with anemia of kidney disease, but its effect has not been studied in randomized trials in cancer patients.. This prospective, multicenter, open-label, randomized trial enrolled 157 patients with chemotherapy-related anemia (Hb

Topics: Abnormalities, Drug-Induced; Administration, Oral; Aged; Anemia; Antineoplastic Agents; Erythropoietin; Female; Humans; Infusions, Intravenous; Iron; Iron-Dextran Complex; Male; Middle Aged; Neoplasms; Prospective Studies; Quality of Life; Recombinant Proteins

There is little experience with the use of various therapies in the end-stage renal disease patient who becomes pregnant. Erythropoietin for the treatment of anemia has become part of the standard treatment regimen of dialysis patients, but experience with its use in pregnancy is limited. We report five cases of its use in dialysis patients during pregnancy. We found no evidence that it crossed the placenta or that it made blood pressure control more difficult. We found that patients required a higher dose of erythropoietin to maintain hematocrit levels than they had before pregnancy. Another therapy involves the treatment for premature labor, which is the most common cause of pregnancy loss in dialysis patients. Two of our patients were successfully treated with indomethacin for premature labor. Both drugs are useful tools in the management of pregnant dialysis patients.

Topics: Abnormalities, Drug-Induced; Adult; Anemia; Erythropoietin; Female; Hematocrit; Humans; Hypertension; Indomethacin; Kidney Failure, Chronic; Obstetric Labor, Premature; Oligohydramnios; Polyhydramnios; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Renal Dialysis